# A Study of MR001 in Patients With Locally Recurrent or Metastatic Advanced Triple-Negative Breast Cancer (TNBC)

> **NCT07208149** · PHASE1,PHASE2 · RECRUITING · sponsor: **Shenzhen Majory Biotechnology Co., Ltd.** · enrollment: 42 (estimated)

## Conditions studied

- Triple-Negative Breast Cancer (TNBC)

## Interventions

- **DRUG:** MR001 Bispecific Antibody for Injection

## Key facts

- **NCT ID:** NCT07208149
- **Lead sponsor:** Shenzhen Majory Biotechnology Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-01-29
- **Primary completion:** 2028-09-01
- **Final completion:** 2028-09-01
- **Target enrollment:** 42 (ESTIMATED)
- **Last updated:** 2026-02-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07208149

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07208149, "A Study of MR001 in Patients With Locally Recurrent or Metastatic Advanced Triple-Negative Breast Cancer (TNBC)". Retrieved via AI Analytics 2026-07-16 from https://api.ai-analytics.org/clinical/NCT07208149. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*